Work

Supplementary Figure 2 from A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study

Year: 2023

Type: supplementary-materials

Abstract: Relative changes (mean and standard deviation) in the number of CTLA4-expressing Tregs with treatment (A). Overall survival of patients with pre-treatment CTLA4 expressing-Treg numbers above and below the median (B).

DOI: 10.1158/1078-0432.22461477

Authors: Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump, Giuseppe Giaccone

Language: English

Topic: Myasthenia Gravis and Thymoma

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361970366

Cites:

Cited by:

Related to: 10